Morgan Stanley raised the firm’s price target on Novo Nordisk to DKK 930 from DKK 800 and keeps an Overweight rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVO:
- Novo Nordisk price target raised to DKK 850 from DKK 650 at Berenberg
- Vivani announces NPM-115 preclinical weight loss data vs. Ozempic /Wegovy
- Viking Therapeutics soars after obesity drug trial hits targets
- Deutsche says Viking data shows GLP-1 market may not be duopoly
- Viking Therapeutics obesity data ‘best-case scenario,’ says Truist